Related Experiment Video
Updated: Apr 24, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.2K
Management strategies for heart failure with preserved ejection fraction
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA; Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit and Institute of Cardiovascular Medicine and Sciences (ICMS), National Heart and Lung Institute (NHLI), Imperial College London, London, UK.
Heart Failure Clinics
|September 14, 2014
Summary
Managing heart failure with preserved ejection fraction (HFpEF) is complex. While no current therapy prolongs survival, treating symptoms and comorbidities can improve quality of life for HFpEF patients.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure with preserved ejection fraction (HFpEF) presents significant management challenges.
- Accurate diagnosis is crucial for effective HFpEF treatment.
- Current therapeutic options for HFpEF lack proven survival benefits.
Purpose of the Study:
- To review current management strategies for HFpEF.
- To provide an overview of clinical trials evaluating HFpEF therapies.
- To highlight novel and promising treatments for HFpEF.
Main Methods:
- Literature review of current HFpEF management.
- Analysis of outcomes from previous HFpEF clinical trials.
- Identification and discussion of emerging therapies for HFpEF.
Main Results:
- Symptomatic improvement and enhanced quality of life are achievable through management of fluid retention and comorbidities like hypertension, myocardial ischemia, and atrial fibrillation.
- Past trials have largely failed to demonstrate significant outcome benefits with tested therapies.
- Novel therapeutic agents show promise for future HFpEF treatment.
Conclusions:
- Effective HFpEF management focuses on symptom control and comorbidity treatment.
- Future research requires precise patient phenotyping for targeted HFpEF therapies.
- Promising novel therapies warrant further investigation in outcome trials.
Related Concept Videos
01:30Heart Failure V: Medical Management
611
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
611
01:22Heart Failure VI: Adjunct Therapies
626
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
626
01:29Cardiomyopathy V: Interprofessional Care
743
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
743
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.6K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.6K
01:30Heart Failure VII: Nursing Interventions
777
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
777
01:30Heart Failure IV: Classification and Diagnostic Evaluation
748
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
748